Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MISSION Therapeutics Receives £20m Series B Funding

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Financing round will enable MISSION to advance its programmes for the treatment of cancers.

Imperial Innovations Group plc has increased its support for MISSION Therapeutics by committing £4.5m of a £20m funding round. Innovations had previously participated in a £6m round for MISSION in August 2011.

MISSION is a biotechnology company developing drugs that target a cell’s response to DNA damage. Innovations is joined in the round by new investor Pfizer Venture Investments and other existing investors Sofinnova Partners, SR One and Roche Venture Fund.

The financing round will enable MISSION to advance its lead programmes for the treatment of various genetically defined cancers, through preclinical development and to exploit further the potential of its novel technology platform.

MISSION was formed to exploit advances in the biology of the DNA damage response for the discovery of new classes of therapeutic agents with novel mechanisms of action.

Utilizing fundamental research principally generated in the laboratory of Professor Stephen Jackson, MISSION has progressed several small molecule discovery programmes focused on key enzymes in the ubiquitin pathway to selectively target difficult-to-treat cancers.

Rob Woodman, Director of Healthcare Investments at Innovations and a non-executive director on MISSION’s board, said: “MISSION’s strong leadership team has made excellent progress in translating fundamental knowledge from the laboratory into a strong drug discovery platform. The VC arms of three of the world’s top five pharmaceutical companies are now supporting MISSION with SR One, Roche Ventures and now Pfizer Ventures investing alongside Innovations, and this is a great endorsement of our model of building companies based on world-class science.”

Michael Moore, Executive Chairman, MISSION, said: “This timely investment will significantly enhance our internal capabilities and strategic goals. It will enable us to build on the Company’s achievements since inception two years ago, strengthen our management team and advance our lead compounds towards the clinic.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica
Cell Medica continue to develop immune reconstitution cell therapies in Europe and to launch new operations in US.
Tuesday, July 24, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Fungi – A Promising Source Of Chemical Diversity
Moulds and plants share similar ways in alkaloid biosynthesis .
Great Migration and African-American Genomic Diversity
Study examines genetic data to analyze regional differences in ancestry.
Faster, More Efficient CRISPR Editing
UC Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!